Highest-materiality recent filing
FDA accepts Inhibrx BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027
FDA accepted BLA for ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma.
Inhibrx Q1 2026 net loss $33.4M; cash $161.7M; ozekibart BLA submitted
Net loss $33.4M ($2.15/sh) vs $43.3M ($2.80/sh) YoY; R&D expense $25.2M down from $36.9M.
Inhibrx: INBRX-106 + pembro achieves 44% ORR vs 21.4% in HNSCC Phase 2
Confirmed ORR 44.0% (11/25) for combo vs 21.4% (6/28) for pembro alone; absolute increase 22.6%.
Inhibrx reports 20% ORR with ozekibart combo in late-line CRC; BLA submitted for chondrosarcoma
ORR of 20% in 45 evaluable patients vs historical 1-6% for standard of care; responses durable >6 months.
Inhibrx reports FY2025 net loss $140.1M; cash $124.2M plus $75M debt draw
Net loss FY2025: $140.1M ($9.04/share), vs FY2024 net income $1.7B from 101 Transaction gain.
Inhibrx reports Q3 net loss $35.3M; ozekibart meets primary endpoint in chondrosarcoma
Net loss of $35.3M ($2.28 per share) vs $43.9M ($2.84) in Q3 2024; R&D expense down to $28.5M.
Ozekibart meets primary endpoint in chondrosarcoma; BLA submission planned Q2 2026
ChonDRAgon study achieved primary endpoint: 52% reduction in risk of progression or death (HR=0.479; p<0.0001); median PFS 5.52 vs 2.66 months.
Inhibrx reports Q2 net loss of $28.7M; cash $186.6M; key trial data expected Q4 2025
Net loss of $28.7M ($1.85/share) vs net income of $1.9B in Q2 2024 due to $2B gain from 101 transaction.
Inhibrx Q1 net loss $43.3M; cash $216.5M after $100M loan; data readouts expected in 2025
Net loss $43.3M ($2.80/share) vs $78.7M ($5.77/share) in Q1 2024.
Inhibrx promotes David Matly to President; CSO Eckelman resigns
David J. Matly appointed President effective April 1, 2025, adding to his role as EVP, Chief Commercial and Business Development Officer.
Inhibrx reports FY2024 net income of $1.7B driven by spin-off gain; secures $100M loan
Net income of $1.7B (EPS $114.01 basic) vs net loss of $241.4M in FY2023; gain from Sanofi INBRX-101 sale.
Inhibrx reports ozekibart Phase 1 CRC data: 40% ORR, median PFS 7.85 months
1 CR, 3 PR among 10 evaluable patients; median PFS of 7.85 months.
Inhibrx secures $150M loan facility from Oxford Finance; $100M funded upfront
Loan and Security Agreement with Oxford Finance for up to $150M term loan; $100M funded on Jan 13, 2025.
Inhibrx Biosciences Q3 net loss $43.9M ($2.84/shr); cash $196.3M; trial readouts in next 12 months
Cash and cash equivalents $196.3M as of Sep 30, 2024, down from $226.9M at June 30, 2024.
Inhibrx wins trade secrets trial against I-Mab; jury rejects all misappropriation claims
Jury found in favor of Inhibrx, rejecting I-Mab's allegations of misappropriation of trade secrets.
Inhibrx Biosciences reports $1.9B net income in Q2 2024 after separation from former parent
Net income of $1.9 billion for Q2 2024, compared to net loss of $47.1 million in Q2 2023
Inhibrx Biosciences completes spin-off from RemainCo, lists 14.5M shares outstanding
Completed spin-off on May 29, 2024; 92% of Inhibrx Biosciences shares distributed to RemainCo shareholders at 1:4 ratio.
Inhibrx Biosciences spin-off registration effective; distribution May 29, merger with Sanofi May 30
Registration statement on Form 10 declared effective by SEC on May 24, 2024.
Mark Lappe will continue in his roles as Chief Executive Officer and Chairperson of the Board of Directors, but will no longer hold the title of President.
On April 1, 2025, Inhibrx Biosciences, Inc. (the “Company”) announced the appointment of David J. Matly, M.B.A. as President, effective April 1, 2025, adding to his current role as Chief Commercial and Business Development Officer.
On March 31, 2025, Brendan P. Eckelman, Ph.D. informed the Company of his intention to resign as EVP, Chief Scientific Officer of the Company, effective immediately, to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer.
Max materiality 0.90 · Median 0.70 · Most common event other_material